In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial Strategies

Set Alert for Commercial Strategies

Exec Chat: J&J’s Menziuso Looks To Extend Vision Care To Underserved Places And People

Johnson & Johnson Vision recently named Peter Menziuso as company group chairman. In a Q&A with Medtech Insight, he his vision for the company and how the company is in a strong position bring vision care to more people.

Exec Chats Diversity & Inclusion

Boston Scientific Plans New Facility In Georgia

The company will invest $62.5m for a new manufacturing and supply chain facility in Johns Creek, GA – about 30 miles northeast of Atlanta in Fulton County, according to Georgia Governor Brian Kemp.

Manufacturing Commercial Strategies

Digital Operating Theater Company Proximie Garners $80m in SoftBank-Jobs Raise

To further expand its digital surgical platform, Proximie has completed a series C funding round, gathering a formidable roster of investors.

Deals Commercial Strategies

Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story

Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.

Exec Chats Cardiovascular

JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.

Coronavirus COVID-19 Sales & Earnings

Podcast: COVID-19 Continues To Shape MTI 100 Entering 2022

In this special podcast, Medtech Insight commercial/R&D editor Reed Miller talks to In Vivo executive editor Ashley Yeo about the annual MTI 100 list and the major trends facing the top medtech companies entering the third year of the pandemic.

Sales & Earnings M & A

MTI 2022 Outlook: The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize

Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the leading global medtechs share their perspectives on the present and the future, from company and health care system standpoints.

Commercial Commercial Strategies

Effective Drug Promotion After COVID: Follow Your Audience

Pharmaceutical marketing and sales shifted toward digital by necessity as the COVID-19 pandemic set in, but advertising experts say offline channels still have an important place in an effective, multi-channel promotional strategy. Defining a brand’s key audience and customer drivers should be the determining factor in channel selection, not chasing the next new media platform.

Commercial Strategies Market Intelligence

Drug Price Reform Concerns Novartis Pharma President

"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke about competitive rebating and new growth opportunities for anchor brands.

Commercial Strategies Commercial

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Coronavirus COVID-19 Leadership

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains. 

Market Access Medical Device

Using Data To Improve Rare Disease Diagnosis And Treatment

A deeper understanding of rare diseases – how they differ across geographies and ethnicities, or which genes and biomarkers are most useful targets for new treatments – can help to accelerate and de-risk clinical trials. On the commercial front, patient data and insights could mean the difference between a category leader and a failure.

Market Intelligence Rare Diseases

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.

Cancer Diagnostic Imaging

New PBM Models Aim To Lower Out-Of-Pocket Costs

Start-up pharmacy benefit managers such as Capital Rx and Evio hope to shake up the traditional PBM service model with increased drug price transparency, aggregated real-world data and outcomes-based contracting. The big three PBMs which dominate the market represent a formidable challenge.

Commercial Market Access

Using Social Media To Engage Patients And Serve Clients

HashtagHealth builds social media campaigns informed by sophisticated social listening, a focus on specific patient needs and a measurable return on investment for clients. 2021 Rising Leader Brittany Latson, a HashtagHealth co-founder, has leveraged her unique career experiences – at Disney, CVS, and advertising agencies large and small – to create a business that reflects her own values and priorities. 

Rising Leaders Commercial Strategies

Outpatient Care, Self-Insured Employers Drive Growth Of Non-Opioid Pain Meds

Opioids are cheap, but the economics of clinical practice, including the shift of care from inside the hospital to outpatient or ambulatory facilities, are creating new opportunities for Pacira BioSciences’ non-opioid treatments for pain. Improved reimbursement and increased usage among anesthesiologists are the biggest revenue drivers for the company’s two marketed products.

Commercial Strategies Companies
See All
UsernamePublicRestriction

Register